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Summary 
In the nonobese diabetic (NOD) mouse,  susceptibility to insulin-dependent  diabetes mellitus 
is in part controlled by a single expressed class II major histocompatibility complex (MHC) molecule, 
I-Ag  7.  This  molecule  probably exerts  its  control  through  the presentation  of a  self-peptide, 
derived from an unknown/3 cell antigen, leading to T cell activation and eventual islet destruction. 
In this paper,  synthetic peptides have been used to compete for binding to the I-As7 molecule 
in an attempt  to suppress the autoimmune response.  The administration  of an I-AgT-binding 
immunogenic peptide, X repressor (cI) 12-26, in a water and oil emulsion (incomplete Freund's 
adjuvant) can prevent the transfer of IDDM into irradiated recipients by spleen cells from diabetic 
donors. Nonbinding,  nonimmunogenic  peptides have no effect in this situation.  However, the 
immune response to the "blocking" peptide in these expei'iments was a complicating factor in 
interpreting  the results.  To establish that  the effect was at the level of competition for MHC 
binding, two additional approaches were tried. First, tolerance was induced to the immunogenic 
peptide, cI 12-26, before using it to "block" disease.  Tolerance abolished the effect on diabetes 
transfer.  Second, an effort was made to identify peptides that were nonimmunogenic but that 
bound to I-Ag  7.  Such a peptide,  mouse prostatic secretory glycoprotein precursor 63-76,  had 
no effect on the incidence of transferred disease.  We conclude that  the "blocking" effects seen 
in initial experiments in the NOD mouse were not caused by blockade of MHC presentation, 
but by other unknown  effects related  to the immunogenicity  of the "blocking"  peptide. 
C 
lass II MHC molecules bind peptide fragments of anti- 
gens for presentation  to helper T  cells.  Peptides com- 
pete for binding  to the class  II molecule,  and competition 
can be used to inhibit T cell activation in vivo (1). The com- 
peting or "blocking" peptide approach has been tested in several 
autoimmune disease models, including experimental autoim- 
mune encephalomyelitis (2, 3), adjuvant arthritis (4), myosin- 
induced acute myocarditis (5), and graft versus host disease (6). 
The nonobese diabetic (NOD) mouse develops a sponta- 
neous autoimmune pancreatic insulitis and has been used as 
a model for human insulin-dependent  diabetes mellitus.  In 
the NOD mouse, the islet cell antigen responsible for initi- 
ating the autoimmune response is unknown,  although  sev- 
eral candidates have been identified (7, 8). The I-As  7 mole- 
cule has a critical role in NOD mouse diabetes, probably in 
the presentation  of an autoantigenic  peptide. 
In this paper, synthetic peptides were used to compete for 
binding to the I-As  7 molecule. Blocking peptide therapy was 
attempted in a transfer system, since diabetes develops rap- 
idly in a high percentage of mice in this model (9). Similar 
work has recently been reported, but in spontaneous disease 
in the NOD mouse (10). The mechanism by which peptide 
"blocking"  occurs in vivo is still not dear. 
Materials and Methods 
Mice.  NOD/Mcd (McDevitt colony) mice and control strains 
were bred within the Stanford Department of Laboratory Animal 
Medicine facility under barrier conditions. The NOD/Mcd mice 
were originally derived from Dr. E. Leiter's colony (The Jackson 
Laboratory, Bar Harbor, ME). The incidence of spontaneous dia- 
betes in the NOD/Mcd colony is "~70% in females and ,,o15% 
in males. Control strains used for immunization  were B10.A(4K) 
(AkEb), BALB/c (AdER), DBA/2J (AdEd), SJL/J (As), PL/J (AuEu), 
BIO.GD (AdEb). 
Peptides.  Peptides were synthesized by 9-fluorenylmethoxycar- 
bow1 chemistry using a peptide synthesizer (model 431A; Applied 
Biosystems, Inc.,  Foster City,  CA),  and they were analyzed by 
reverse-phase HPLC, amino acid composition, and mass spectrom- 
etry. Peptides used in blocking experiments were HPLC purified. 
T CellProliferation  Assays.  NOD mice and the appropriate con- 
trol strain were immunized  in the the tail base or footpad with 
antigen emulsified in CFA. The antigen was dissolved in PBS at 
a concentration  of 2 mg/ml and mixed 1:1 with CFA. Mice were 
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Volume 182  September 1995  897-902 Table  1.  Antigens  Tested for T  Cell Proliferation in  the NOD Mouse 
MHC  Immune  Binding 
Antigen  Residues  Sequence  restriction  response  to  I-As7 
OVA 
Whole OVA 
OVA  323-339 
EMb 
Whole EMb 
EMb  102-118 
131-153 
Rat myelin basic protein (rMBP) 
Whole rMBP 
rMBP 
HEL 
Whole HEL 
HEL 
cI 
Whole cI 
cI 
Ac1-11 
35-47 
89-101 
13-35 
46-61 
74-96 
1-102 
12-26 
73-88 
Influenza hemagglutinin HA/PR8  (Flu HA) 
Flu HA  111-120 
130--142 
Staphylococcal nuclease (SNase) 
SNase  61-79 
Tuberculosis 65-kD heat  shock protein (TB) 
TB  112-126 
Bovine cytochrome C  (BCC) 
BCC  13-25 
Reiterative peptides 
ROIV 
RLI 
Murine -peptides 
o~-1 antitrypsin  148-163 
Laminin bl  chain 
precursor  1594-1612 
PSG-1  63-76 
Mouse lysozyme  13-39 
Murine myoglobin  131-153 
ISQAVHAAHAEINEAGR 
KYLEFISDAIIHVLHSK 
MTKALELFRNDIAAKYKELGFQG 
+ 
A d  +  + 
+ 
A  d  _  _ 
A d  +  + 
+ 
AcASQKRPSQRHG  A u  - 
TGILDSIGRFFSG  E u  - 
VHFFKNIVTPRTP  A s  - 
KRHGLDNYRGYSLGNWVCAAKFE  A a 
NTDGSTDYGILQINSR  A = 
NLCNIPCSALLSSDITASVNCAK  E k,  A b 
LEDARRLKAIYEKKK  E d'k 
VEEFSPSIAREIYEMY  H-2  ~b 
FERFEIFPKE  A d 
HNTNGVTAACSHE  A a 
FTKKMVENAKKIEVEFDKG  A d 
YEKIGAELVKEVAKK  H-2  b'd'k 
KCAQCHTVEKGGK  A d 
AHAAHAAHAAHAAHAA  A a 
ARRLKARRLKARRLK  E a 
LSQAVHKAVLTIDETG 
MVKEALEEAEKAQVAAEKA 
FENRKRIEPVLIRK 
KRNGMAGYYGVSLADWV 
MSKALELFRNDIAAKYKELGFOG 
+ 
+  + 
+ 
+  + 
+  + 
+  + 
+  + 
-  + 
+  + 
Positive lymph node T cell proliferative responses are indicated. When tested, binding of peptides to I-As  7 in hybridoma competition assays is shown. 
The sequence data for PSG, antitrypsin, and mouse lysozyme C are availab]e under the SwissProt data base under accession numbers P09036, P07758, 
and P08905, respectively. 
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antigen. Draining lymph nodes were removed 10-14 d later, and 
5  x  10  s cells were cultured for 3 d in the presence of antigen in 
a total volume of  200/zl RPM11640 supplemented  with 1% mouse 
serum, 2 mM ghtamine, 10 mM Hepes, 50/zM 2-ME, 100 U/ml 
penicillin, and 100 ttg/ml streptomycin. The cells were then pulsed 
with 0.5/zCi [3H]thymidine per well before being harvested for 
liquid scintillation counting "~18 h later. 
Adoptive Transf~  Spleens  from diabetic females  were disrupted 
in PBS, and red cells  were lysed  with Tris-buffered  ammonium chlo- 
ride. The cells were then washed and taken up in RPMI 1640. 8-12- 
wk-old male NOD mice were irradiated with 650 rads from a 
250-kV x-ray source and were then injected via the tail vein with 
107 spleen cells in a 0.2-ml vol. Mice were monitored from day 
14 until day 28  with urinary  glucose testing  (Chemstrip  uG; 
Boehringer Mannheim Biochemicals,  Indianapolis,  IN). Blood gh- 
cose was measured on day 28 (Accu-Chek IIm; Boehringer Mann- 
heim Biochemicals, Indianapolis, IN). 
Peptide Treatment.  In the adoptive transfer experiments, pep- 
tides were dissolved in PBS and emulsified in IFA. IFA was used 
to provide a s]ow release of peptide during "~6-7 d. Peptides were 
administered intraperitoneally in a 0.2-ml vol. 
Peptide Tolerization.  Peptide  was dissolved  in PBS, sterile  filtered, 
and spun twice at 13,000 rpm for 5 min to remove possible ag- 
gregates. Diabetic female donor mice were given two doses of ei- 
ther 600/zg or 1.2 mg ofc112-26 peptide intravenously  in a 0.2-ml 
vol 10 and 5 d before the experiment. Diabetic female mice in this 
experiment were maintained on 5 U lente insulin (Lente Iletin 100 
suspension; Lily) subcutaneously  every 2 d. To prove that toleriza- 
tion was effective, test mice were tolerized and then immunized 
with )~ repressor (cI) 12-26 in CFA, and lymph node assays  were 
set up as described. 50/zl of supernatant was removed from each 
well after 24 h for Ib2 assay  as described  below, while the remaining 
culture  was pulsed with [3H]thymidine after 48  h  to measure 
proliferation. 
Profile Searching.  The programs PileUp and ProfileMake  from 
the Sequence  Analysis  Software  Package  (Genetics  Computer Group, 
Madison, WI) (11) were used to identify nonimmunogenic pep- 
tides. Profiles were made from OVA 323-339, cI 12-26, Staphylo- 
coccal nuclease 61-79, and hen egg lysozyme (HEL) 13-35. The 
profiles were run against the entire mouse protein database using 
Profilescarch. The three best matches were synthesized and tested: 
prostatic secretory glycoprotein precursor (PSG)-I 63-76 (FEN- 
RKRIEFVLIRK), mouse c~-1 antitrypsin (AT) 148-163 (LSQAVH- 
KAVLTIDETG), and mouse lysozyme  C (ML) 13-29 (KRNGMA- 
GYYGVSLADWV). The peptides were tested for immunogenidty 
in lymph node proliferation assays and for binding  to I-A87 by 
competition for presentation to a cI 12-26--specific  T cell hybridoma. 
Hybridoma Competition Assays.  A  cI  12-26-specific I-As7- 
restricted T cell  hybridoma, 2.2E9, was produced  by fusion of  NOD 
lymph node cells  with the BW5147 cell  line. For competition assays, 
cI 12-26 was plated over a 0.625-5/tM range in triplicate, and com- 
petitor peptide was then added at a constant concentration of 0.5 
mg/ml (,,~250/tM). Next, 10  s cells of an I-As7-expressing trans- 
fectant, M12.NOD  (made by Dr. Steven Singer, Harvard School 
of Medicine, Boston, MA), and finally 10  s 2.2E9 cells were added 
to a total volume of 200/zl. After 24 h, 50/~1 of supernatant was 
removed, frozen, and hter added to 104 HT-2 cells. HT-2 cells were 
cultured for 24 h, with the addition of 1/tCi [3H]thymidine per 
well for the last 6 h of culture, before harvesting and counting. 
Results 
NOD Mouse T CelIResponses.  Lymph node T cell prolifer- 
ative responses were used as an initial screen for peptides that 
bound  to  I-As  7.  Several whole  antigens,  and  a  pand  of 
known T cell epitopes were tested (Table 1). Five T cell epi- 
topes that are highly immunogenic in the NOD mouse (Table 
2) have been identified. One of these peptides, cI 12-26, was 
then tested for its ability to block adoptively transferred dia- 
betes in the NOD mouse. Whole OVA and two nonimmuno- 
genie peptides were also  tested initially. 
Prevention of  Adoptive Transfer by Immuogenic Peptides.  Pep- 
tide blocking was tested in an adoptive transfer system, since 
diabetes  develops  in 80-100%  of mice within 2-4  wk of 
transfer, compared with 3-6 mo for spontaneous disease. Pep- 
tides were administered intraperitoneally at a dose of 2 mg 
in IFA per mouse given at the time of transfer.  Mice were 
monitored starting on day 14 until day 28 with urinary glu- 
cose testing and blood glucose measurement at the end of 
the experiment. Diabetes was defined as a blood glucose of 
I>200 mg/dl. 
In initial experiments,  a reduction in the incidence of adop- 
tively transferred diabetes in the NOD mouse was seen after 
treatment with cI 12-26 (Fig.  1 a). Similar results were seen 
in a repeat experiment. This reduction in disease was also 
observed with whole OVA, another immunogen in the NOD 
mouse (Fig.  1 b). Treatment with the nonbinding peptides 
cI 73-88 or equine myoglobin (EMb) 102-118 had no effect 
on disease incidence (Fig.  1, c and d). 
The immune response to the "blocking" peptide in these 
experiments, however, was a complicating factor in interpreting 
the results. To establish that the effect was at the level of com- 
petition for MHC binding, two further approaches were tried. 
Table  2.  Peptides  Eliciting a Positive T  Cell Response in the NOD Mouse 
Known MHC 
Peptide  Sequence  restriction 
OVA 323-339  I SQAVHAAHAE I NEAGR  A a 
cI  12-26  LEDARRLKA I YEKKK  A a, E  d. k 
Staphylococcal nuclease 61-79  FTKKMVENAKK I EVEFDK  A  d 
EMb  131-153  MTKALELFRND I AAKYKELGFQG  E  a, k 
HEL  13-35  KRHG LDNYRGYSLGNWVCAAKFE  A a 
The peptides listed produced strong proliferative  responses in lymph node T cell assays; murine peptides tested are not shown. 
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Figure  1.  Adoptive  transfer experiments 
with  immunogenic  and  nonimmunogenic, 
nonbinding peptides in the NOD mouse. The 
number of diabetic mice over the total number 
of mice is shown to the right  of each treat- 
ment. Disease inhibition (a) with cI 12-26 and 
(b) with whole OVA. Lack of disease inhibi- 
tion with the nonimmunogenic, nonbinding 
peptides  (c) cI 73-88 and  (d) EMb 102-118. 
Peptide Treatment after Tolerization.  Tolerance  to a peptide 
can be induced by giving  it in soluble form intravenously 
in PBS before immunization.  Two doses of at least 300 #g 
given 10 and 5 d before immunization induce tolerance lasting 
up to 120 d (11a). cI 12-26 is strongly immunogenic in NOD 
and BALB/c mice. To prove that this tolerizing regimen was 
effective,  NOD and BALB/c control mice received two doses 
of 600/~g  cI  12-26 intravenously in PBS before being im- 
munized  with  100/~g  of the  same  peptide  in  CFA.  The 
proliferative response after tolerization was reduced by "~50% 
(data  not  shown),  and  the IL-2  response  was reduced by 
80-90%  (Fig.  2 a). 
A transfer experiment was then done after tolerization to 
the blocking peptide cI 12-26.  In this experiment,  diabetic 
female donor mice were tolerized  with  1.2 mg of peptide 
at days -  10 and -  5. Recipient mice received two 3-mg doses 
of cI 12-26 in IFA on the day of transfer and 7 d after transfer. 
The reduction in disease seen in the previous nontolerized 
experiments was abolished (Fig.  2  b).  Similar results were 
found on repeating  this experiment  once. 
Peptide Treatment with a Noniraraunogenic Peptide.  Several 
peptides  derived  from murine protein  sequences were  also 
tested as potential blockers. These sequences were homolo- 
gous to previously identified epitopes and were identified using 
ProfileMake  and  ProfileSearch  from  the  GCG  software 
package.  Of the peptides tested, only PSG-1 63-79 was both 
nonimmunogenic when NOD mice were immunized with 
100/~g  in CFA in footpads (Fig.  3 a)  and bound to I-Ag  7 
(Fig. 3 b). PSG-1 63-79 was then used in a blocking experi- 
ment, with 2 mg being given in IFA at the time of transfer. 
This treatment had no effect on the incidence of transferred 
diabetes  (Fig.  3  c). 
a  b 
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Figure  2.  (a)  Peptide  tolerization. 
Peptide was dissolved in PBS, sterile ill- 
tered, and spun twice at 13,000 rpm for 
5 min to remove possible aggregates. 
In the experiment  shown,  mice were 
tolerized  with two doses of 300/~g cI 
12-26 intravenously in PBS and then im- 
munized with 100/~g cl 12-26 in CFA 
in the footpads. Lymph node assays were 
set up as described.  50/zl of superna- 
tant was removed from each well after 
24  h  for  IL-2 assay with  HT-2  calls, 
while the remaining culture was pulsed 
with [3H]thymidine after 48 h to mea- 
proliferation.  Ib2 production is significantly  reduced in T  cell supernatants  from NOD and BALB/C mice tolerized by the protocol described.  (b) 
Adoptive  transfer and treatment  with cI 12-26 after previous tolerization  to the peptide.  In this experiment,  diabetic female donor mice were given 
two 1.2-mg doses ofcl 12-26 peptide intravenously in a 0.2-ml vol 10 and 5 d before the experiment.  Spleen cells from these mice were then transferred 
into irradiated male recipients. The transferred mice were tested for glycosuria as described. No reduction in diabetes incidence was seen after previous 
tolerization  with the blocking peptide. 
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Figure 3.  (a) NOD mouse immunizations with routine self-peptides  in CFA. (b) Binding of murine peptides to I-Ag  7, as measured by competition 
for presentation to the cI 12-26-specific  hybridoma 2.2E9. For competition assays, cl 12-26 peptide was added first to a 96-well plate in triplicate over 
a 0.625-5 #M concentration range. Next, competitor peptide was added at a constant concentration of 0.5 mg/ml ("~250 #M) to all the wells. 10  s 
cells of an I-AgT-expressing  transfectant (M12.NOD) were then added, and finally 10  s 2.2E9 cells were added to a total volume of 200 #1. After 24 
h, 50 #1 of supernatant was removed, frozen, and later added to 104 HT-2 cells. HT-2 cells were cultured for 24 h with the addition of I #Ci [3H]thymidine 
per well for the last 6 h of culture, before harvesting and counting. (c) Adoptive transfer and treatment with the nonimmunogenic but I-AsT-binding 
peptide PSG-1 63-76. In this experiment, irradiated, spleen cell recipient male NOD mice were each given 2 mg of PSG-1 63-76 dissolved in PBS 
and emulsified in IFA. The peptide was administered intraperitoneally in a 0.2-ml vol. Mice were tested for glycosuria as described. 
Discussion 
In summary, from these experiments, it now appears that 
"blocking" of diabetes transfer observed with cI 12-26 (or 
with  whole OVA)  was  the result  of an immune  response 
directed against  the peptide.  A  spleen cell proliferative re- 
sponse could be detected when peptide was given in this form, 
i.e.,  intraperitoneally in IFA or in  slow-release pellet form 
(Innovative  Research  of America,  Toledo,  OH),  where  a 
blocking effect was  also  seen (Fig.  4). 
When an immunogenic peptide (cI 12-26) was given after 
tolerization or when a nonimmunogenic non-binding pep- 
tide (cI 73-88, or EMb 102-118) was used, there was no effect 
on diabetes incidence. A  nonimmunogenic but I-AsT-hinding 
peptide  (PSG-1  63-79),  also had no effect on disease.  The 
"blocking" effect on disease with cI 12-26 in the naive an- 
imal was therefore not caused by competitive binding to class 
II  MHC,  but  was  related  to  the  immunogenicity  of the 
blocking peptide.  In an additional experiment,  spleen cells 
were pulsed with 100 #M ~, cI 12-26 for 6 h in culture before 
transfer into irradiated recipient mice. There was  no effect 
on the incidence of diabetes between the group transferred 
with cells treated in this way and a control group, again ar- 
guing  against  a direct blocking effect (data not  shown). 
In the NOD mouse, any stimulation oftbe immune system 
appears to lower the incidence of disease.  For example, the 
incidence of diabetes is higher in a "clean" mouse colony than 
in a "dirty" colony, where infections presumably stimulate 
the immune system. Immunization with CFA alone will pre- 
vent disease in the NOD mouse (12). The incidence of NOD 
mouse diabetes is also sensitive to a number of other factors, 
for example diet and local colony conditions (13). The genera- 
tion of an additional alternative immune response may divert 
cells away from the pancreas, perhaps ~.lter the balance between 
Thl and Th2 cells and alter cytokine levels (14), or shift the 
balance between  diabetogenic and  suppressor T  cells (15). 
It has been reported that a peptide can block the sponta- 
neous development of diabetes in the NOD mouse by inter- 
fering with antigen presentation (10).  For the reasons dis- 
cussed, caution is needed in accepting these results. It is dear 
that the "blocking" peptide was provoking a significant im- 
mune response in these experiments.  In fact,  the mice re- 
quired coadministration  of an antihistamine  to prevent an 
anaphylactic reaction. The only peptide control provided was 
a group treated with a nonimmunogenic,  nonbinding pep- 
tide. The experiments should perhaps also have included an 
MHC-binding,  but  nonimmunogenic,  peptide. 
Blocking peptides fall into two main categories, those that 
are related to the disease-initiating peptide and those that are 
unrelated. Related peptide analogues may be able to engage 
the TCR and cause differential signaling through it (16). The 
net result may depend on the affinity of this interaction with 
the  TCR.  Some  analogues  such  as  myelin  basic  protein 
go 
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Figure 4.  Transfer  of insulin-dependent  diabetes  mellitus and treatment 
with cI 12-26  in slow-release  pellet form. Irradiation and transfer  was done 
as described  in Materials and Methods. Transferred  mice were treated with 
two pellets placed subcutaneously  containing a total of 2 mg cI 12-26 pep- 
tide. Mice were tested for glycosuria as described. 
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anergy or cause T  cell deletion. This type of peptide may 
be able to treat disease, as well as to prevent it (18). 
The use of related peptides is clearly only possible in a dis- 
ease model where the autoantigen is known. Experimental 
autoimmune encephalomyelitis has been prevented with un- 
related peptides,  but here,  the competing peptide has been 
given at the same time as the disease-inducing peptide, thus 
preventing induction of disease. In the NOD mouse, T cells 
were already primed against the autoantigen at the time of 
transfer and treatment. In NOD mouse diabetes, the affinity 
of the autoantigenic peptide(s)  may be very high, making 
competition difficult. In a spontaneous disease model such 
as the NOD mouse, there may be several epitopes from more 
than one autoantigen being presented. Specific peptide im- 
munotherapy in this model may be feasible once these au- 
toantigenic peptides have been identified. 
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